Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | CLK2 | P49760 | 1/20 | 0.73 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL9773903 | 0.99 | KCNH2 (0.73) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL5570141 | 0.93 | KCNH2 (0.79) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL6169394 | 0.93 | KDM4E (0.69) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL6167197 | 0.93 | KDM4E (0.69) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| Water SCHEMBL9773975 | 0.93 | KCNH2 (0.78) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL6458734 | 0.92 | KDM4E (0.75) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL6169491 | 0.92 | KCNH2 (0.67) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL6169566 | 0.92 | KCNH2 (0.67) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| Hydrochloric Acid SCHEMBL6167081 | 0.92 | KDM4E (0.68) | KCNH2KDM4EALDH1A1HPGDPOLB | |
| SCHEMBL5571094 | 0.92 | KCNH2 (0.74) | KCNH2KDM4EALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730154-B1 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE IP VENTURES L P (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1730154-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005070940-A2 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | RIF1, MRPL37, AURKAIP1 | KCNH2 3101/4885KDM4E 2995/4885ALDH1A1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.